If you happened to listen to their last presentation, they are "evaluating" an expansion cohort in MM.....hardly an endorsement of efficacy.
So, now theyre stuck with DLBCL when other companies are now getting multiple CRs in early studies in this indication.
Move on to CUDC-427. Novartis testing their IAP in MM, MDS, lymphomas, ovarian, breast, MF. Curis decides to stick to MALT lymphomas as one heavy concentration along with ovarian. MALT lymphoma....an indication which can be cured early with antibiotics.
Market Data 
Markets 
AI
